Entrada Therapeutics, Inc. (TRDA)

Market Cap	452.30M
Revenue (ttm)	87.17M
Net Income (ttm)	-21.77M
Shares Out	33.34M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,463
Open	13.80
Previous Close	13.78
Day's Range	13.25 - 13.80
52-Week Range	9.32 - 21.64
Beta	-0.56
Analysts	Strong Buy
Price Target	20.00 (+49.7%)
Earnings Date	Nov 7, 2023

About TRDA

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 29, 2021
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: TRDA

Analyst Forecast

According to one analyst, the rating for TRDA stock is "Strong Buy" and the 12-month stock price forecast is $20.0.

Price Target

$20.0

(49.70% upside)

Analyst Consensus: Strong Buy